This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sandborn WJ (2003) Preventing antibodies to infliximab in patients with Crohn's disease: optimize, not immunize. Gastroenterology 124: 1140–1145
Maini R et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT study group. Lancet 354: 1932–1939
Rutgeerts P et al. (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126: 402–413
Baert F et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601–608
Farrell RJ et al. (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124: 917–924
Acknowledgements
The synopsis was written by Minal Chande, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ghosh, S. Maintenance therapy versus episodic therapy with infliximab for Crohn's disease. Nat Rev Gastroenterol Hepatol 1, 80–81 (2004). https://doi.org/10.1038/ncpgasthep0039
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep0039